This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Verenium Corporation's CEO Discusses Q2 2011 Results - Earnings Call Transcript

The company’s actual results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, those discussed in our filings with the SEC, but not limited to our reported on Form 10-K for the year ended December 31st, 2010. These forward-looking statements speak only to the date hereof.

I will now turn the call over to Jamie.

James Levine

Thanks, Kelly and good afternoon everyone and thanks for joining us on our second quarter earnings call. I’d like to begin today’s call by giving a quick recap of the strategy we laid out at our Analyst and Investor Day in June and then, I’ll discuss some of the milestones we’ve achieved in the first half of the year that demonstrate we are indeed successfully executing against our business plan. And finally, I’ll end with some thoughts on our current market valuation.

Our Analyst and Investor Day was an important opportunity for us to provide a detailed view of where the company is today and our plan to realize transformational growth over the next several years. Finally, we laid out the milestones against which stakeholders can judge our execution of that plan and which will position us to become a major industrial enzymes player in a market currently dominated by two players.

So, to summarize the Capital Markets Day, in the industrial biotech space, Verenium has it all. We have the leading product development technology and we have proof of that claim through a portfolio of top-performing products. We have a deep pipeline of new products, attracting industry leading partners and finally, our resources are targeted at multiple, fast growing and highly profitable markets that exist today.

Looking at each component of that vision, I’ll start with our market. In the last 12 months, we had 53 million of product sales into end markets that we estimate at over $1 billion, which is only a fraction of the $3 billion market for industrial enzymes which is projected to grow to nearly 4.4 billion by 2015. What’s more of that growth it’s being catalyzed by significant worldwide trends of first meeting food needs for growing populations.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
GOOG $693.01 0.00%
FB $117.58 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs